BACKGROUND: Prospective studies of serum albumin concentration measurement as a low-cost predictor of human immunodeficiency virus (HIV) disease progression are needed for individuals initiating antiretroviral therapy (ART) in resource-limited settings. METHODS: Serum albumin concentration was measured at ART initiation for 2145 adults in Tanzania who were enrolled in a trial examining the effect of multivitamins on HIV disease progression. Participants were prospectively followed for mortality, morbidity, and anthropometric outcomes at monthly visits (median follow-up duration, 21.2 months). Proportional hazard models were used to analyze mortality, morbidity, and nutritional outcomes, while generalized estimating equations were used to analyze CD4(+) T-cell counts. RESULTS: Individuals with hypoalbuminemia (defined as a serum albumin concentration of <35 g/L) at ART initiation had a hazard of death that was 4.52 times (95% confidence interval, 3.37-6.07; P < .001) that of individuals with serum albumin concentrations of ≥ 35 g/L, after multivariate adjustment. Hypoalbuminemia was also independently associated with the incidence of pulmonary tuberculosis (P < .001), severe anemia (P < .001), wasting (P = .002), and >10% weight loss (P = .012). Secondary analyses suggested that serum albumin concentrations of <38 g/L were associated with increased mortality and incident pulmonary tuberculosis. There was no association between serum albumin concentration and changes in CD4(+) T-cell counts (P = .121). CONCLUSIONS: Serum albumin concentrations can identify adults initiating ART who are at high risk for mortality and selected morbidities. Future research is needed to identify and manage conditions that reduce the serum albumin concentration.
BACKGROUND: Prospective studies of serum albumin concentration measurement as a low-cost predictor of human immunodeficiency virus (HIV) disease progression are needed for individuals initiating antiretroviral therapy (ART) in resource-limited settings. METHODS: Serum albumin concentration was measured at ART initiation for 2145 adults in Tanzania who were enrolled in a trial examining the effect of multivitamins on HIV disease progression. Participants were prospectively followed for mortality, morbidity, and anthropometric outcomes at monthly visits (median follow-up duration, 21.2 months). Proportional hazard models were used to analyze mortality, morbidity, and nutritional outcomes, while generalized estimating equations were used to analyze CD4(+) T-cell counts. RESULTS: Individuals with hypoalbuminemia (defined as a serum albumin concentration of <35 g/L) at ART initiation had a hazard of death that was 4.52 times (95% confidence interval, 3.37-6.07; P < .001) that of individuals with serum albumin concentrations of ≥ 35 g/L, after multivariate adjustment. Hypoalbuminemia was also independently associated with the incidence of pulmonary tuberculosis (P < .001), severe anemia (P < .001), wasting (P = .002), and >10% weight loss (P = .012). Secondary analyses suggested that serum albumin concentrations of <38 g/L were associated with increased mortality and incident pulmonary tuberculosis. There was no association between serum albumin concentration and changes in CD4(+) T-cell counts (P = .121). CONCLUSIONS: Serum albumin concentrations can identify adults initiating ART who are at high risk for mortality and selected morbidities. Future research is needed to identify and manage conditions that reduce the serum albumin concentration.
Authors: Usha S Govindarajulu; Donna Spiegelman; Sally W Thurston; Bhaswati Ganguli; Ellen A Eisen Journal: Stat Med Date: 2007-09-10 Impact factor: 2.373
Authors: Christine N Dao; Philip J Peters; James N Kiarie; Isaac Zulu; Peter Muiruri; John Ong'ech; Winfred Mutsotso; Dara Potter; Lungowe Njobvu; Jeffrey S A Stringer; Craig B Borkowf; Omotayo Bolu; Paul J Weidle Journal: AIDS Res Hum Retroviruses Date: 2011-05-04 Impact factor: 2.205
Authors: D Fouque; K Kalantar-Zadeh; J Kopple; N Cano; P Chauveau; L Cuppari; H Franch; G Guarnieri; T A Ikizler; G Kaysen; B Lindholm; Z Massy; W Mitch; E Pineda; P Stenvinkel; A Treviño-Becerra; A Trevinho-Becerra; C Wanner Journal: Kidney Int Date: 2007-12-19 Impact factor: 10.612
Authors: Susan M Graham; Jared M Baeten; Barbra A Richardson; Mark H Wener; Ludo Lavreys; Kishorchandra Mandaliya; Jeckoniah O Ndinya-Achola; Julie Overbaugh; R Scott McClelland Journal: AIDS Res Hum Retroviruses Date: 2007-10 Impact factor: 2.205
Authors: Jared M Baeten; R Scott McClelland; Mark H Wener; Daniel D Bankson; Ludo Lavreys; Kishorchandra Mandaliya; Job J Bwayo; Joan K Kreiss Journal: Int J STD AIDS Date: 2007-03 Impact factor: 1.359
Authors: William Worodria; Marguerite Massinga-Loembe; Harriet Mayanja-Kizza; Jane Namaganda; Andrew Kambugu; Yukari C Manabe; Luc Kestens; Robert Colebunders Journal: Clin Dev Immunol Date: 2010-12-08
Authors: Andreas Ronit; Shweta Sharma; Jason V Baker; Rosie Mngqibisa; Tristan Delory; Luis Caldeira; Nicaise Ndembi; Jens D Lundgren; Andrew N Phillips Journal: J Infect Dis Date: 2018-01-17 Impact factor: 5.226
Authors: Mark W Tenforde; Nikhil Gupte; David W Dowdy; David M Asmuth; Ashwin Balagopal; Richard B Pollard; Patcharaphan Sugandhavesa; Javier R Lama; Sandy Pillay; Sandra W Cardoso; Jyoti Pawar; Breno Santos; Cynthia Riviere; Noluthando Mwelase; Cecilia Kanyama; Johnstone Kumwenda; James G Hakim; Nagalingeswaran Kumarasamy; Robert Bollinger; Richard D Semba; Thomas B Campbell; Amita Gupta Journal: PLoS One Date: 2015-02-26 Impact factor: 3.240
Authors: Tom Were; Jesca O Wesongah; Elly Munde; Collins Ouma; Titus M Kahiga; Francisca Ongecha-Owuor; James N Kiarie; Aabid A Ahmed; Ernest P Makokha; Valentine Budambula Journal: BMC Clin Pathol Date: 2014-07-09